Premium
Healing of a resistant neurotrophic corneal ulcer using a new matrix therapy agent ( RGTA ): A case report
Author(s) -
Zghal I.,
Zahaf A.,
Fekih O.,
Zayani M.,
Bouguila H.,
Nacef L.
Publication year - 2015
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2015.0700
Subject(s) - medicine , extracellular matrix , surgery , wound healing , transplantation , neurotrophic factors , cataract surgery , cornea , artificial tears , corneal ulcer , neurotrophin , ophthalmology , receptor , biology , microbiology and biotechnology
Purpose We report a case of a resistant neurotrophic corneal ulcer successfully treated by the matrix regenerating agent ( RGTA ) Cacicol( ® ). Methods We report a case of an 18‐year‐old female patient, who developed a persistent epithelial ulcer after cataract surgery complicated by endophthalmitis, with no improvement despite 4 weeks of artificial tears. A new ophthalmologic solution based on a regenerating agent ( RGTA , Cacicol20 ® ) was then used, with a dosage of two eye drops per week for 8 weeks. Results Improvement was observed in 2 weeks, and complete healing was obtained in <5 weeks, with no side effects. Conclusions This heparin mimetic, which may stimulate extracellular matrix healing, may be a possible alternative therapy to autologous serum or amniotic membrane transplantation in severe neurotrophic ulcer. However, randomized studies are necessary to confirm this encouraging result.